Related references
Note: Only part of the references are listed.Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis
Hui-Hua Chang et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2010)
Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient
D. Capone et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2010)
Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients
T. Mori et al.
BONE MARROW TRANSPLANTATION (2009)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Gregory M. Cooper et al.
BLOOD (2008)
Genotyping panel for assessing response to cancer chemotherapy
Zunyan Dai et al.
BMC MEDICAL GENOMICS (2008)
Pharmacogenetics in Breast Cancer Therapy
Sing-Huang Tan et al.
CLINICAL CANCER RESEARCH (2008)
Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation
A. H. Elmaagacli et al.
BONE MARROW TRANSPLANTATION (2007)
The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?
DA Hesselink et al.
PHARMACOGENOMICS (2005)
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation
D Anglicheau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
V Haufroid et al.
PHARMACOGENETICS (2004)
Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance
C Marzolini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Genomic medicine - Inheritance and drug response.
R Weinshilboum
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Share Paper
